TWST Twist Bioscience Corporation
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel floor · 12-month channel rising
Price is on the lower line, where it has held before.
- 9-month channel
- US$146.72 – US$264.82 · rising, more than +100% a year
- 12-month channel read from
- US$145.62 – US$262.62 · rising, more than +100% a year
- Price in channel
- 6.0% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$262.62
- Turns bearish below
- US$145.62
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 4:05 PM ET (44 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$139.05
level as at 1 Dec 2026
Our target
US$173.82
by 14 Nov 2026
Projected move
25.0%
gross, before costs
Price is between our buy and target.
Target: TWST's usual move size (25.0%), the best return per day on this path.
This move size: reached in 38% of 22 past stretches, typically in 34 days. (0.74% per day)
- Upper line touches
- 2
- Lower line touches
- 3
- Fit confidence
- 66%
- Fitted
- 1 Nov 2026
Company information
About Twist Bioscience Corporation
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Emily Marine Leproust
- Employees
- 979
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$8.74B
- Enterprise value
- —
- Beta
- 2.19
- Avg volume
- 2.12M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 23.3-219.71
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.